This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Versaci, F. Articles by Crea, F. Search for Related Content PubMed PubMed Citation Articles by Versaci, F. Articles by Crea, F.

Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study)

Francesco Versaci, MD, FACC^*,*, Achille Gaspardone, MPhil, MD, FACC^*, Fabrizio Tomai, MD, FACC^*, Flavio Ribichini, MD, Paolo Russo, MD, Igino Proietti, MD^*, Anna Silvia Ghini, MD^*, Valeria Ferrero, MD, Luigi Chiariello, MD, FACC^*, Pier Agostino Gioffrè, MD^¶, Francesco Romeo, MD, FACC and Filippo Crea, MD, FACC^||

^* Cattedra di Cardiochirurgia, Università Tor Vergata, Rome, Italy
Divisione di Cardiologia, Università del Piemonte Orientale, Novara, Italy
Divisione di Cardiologia, Ospedale S. Croce e Carle, Cuneo, Italy
Cattedra di Cardiologia, Università Tor Vergata, Rome, Italy/AFF
^|| Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome, Italy
^¶ European Hospital, RomeItaly

View larger version (11K): [in a new window]   Figure 1 Event-free survival (death, myocardial infarction, recurrence of symptoms requiring additional revascularization) curves of the two study groups at 12-month follow-up. The rate of event-free survival was significantly higher in the prednisone group than in the placebo group (p < 0.0016 by Cox proportional hazards regression analysis).

View larger version (12K): [in a new window]   Figure 2 Cumulative frequency distribution curves showing the percentage of stenosis measured at six-month angiographic follow-up. The vertical broken line indicates the percentage of patients with (right of the line, 33% vs. 7% in placebo [dashed line] and prednisone [solid line] groups, respectively) and without restenosis (left of the line, 67% vs. 93% in placebo and prednisone groups, respectively).